OVID

Ovid Therapeutics Inc. (OVID) - Q3 2025 10-Q Summary

Business Context and Reporting Period

Ovid Therapeutics Inc. is a biopharmaceutical company developing small molecule medicines for brain conditions with significant unmet need, focusing on epilepsy and psychoses. This report covers the quarterly period ended September 30, 2025. The Company is classified as a non-accelerated filer and a smaller reporting company. As of November 7, 2025, there were 71,212,353 shares of common stock outstanding.

Key Financial Metrics

Note: Revenue for the nine months ended September 30, 2025, includes a $6.3 million one-time payment from an amended license agreement with Immedica (formerly Marinus Pharmaceuticals).

Material Changes vs. Prior Period

• Revenue Surge: YTD revenue increased by $6.04 million compared to the prior year, driven primarily by the $7.0 million settlement with Immedica regarding the ganaxolone license, of which $6.3 million was recognized in Q2 2025.
• Expense Reduction: Total operating expenses decreased by $14.97 million YTD compared to 2024. Research and Development (R&D) expenses dropped $11.85 million, largely due to the pause of the OV888 (GV101) program and cost reductions from an organizational restructuring in June 2024.
• Other Income Volatility: Other income (expense), net decreased by $30.9 million YTD. The prior year included a $29.0 million gain from the adjustment of the royalty monetization liability related to the discontinued soticlestat program, which did not recur in 2025.
• Asset Base: Total assets decreased from $92.2 million to $63.8 million, reflecting the drawdown of marketable securities to fund operations.

Guidance, Outlook, and Risks

• Liquidity and Financing: As of September 30, 2025, the Company held $25.6 million in cash and marketable securities. On October 2, 2025 (subsequent to the period end), Ovid completed a private placement raising approximately $75.7 million in net proceeds. Management believes this capital is sufficient to fund operations for at least 12 months.
• Pipeline Updates: On October 3, 2025, the Company announced positive topline Phase 1 data for OV329, a next-generation GABA-aminotransferase inhibitor. The OV888 program remains paused.
• Nasdaq Compliance: The Company previously faced delisting risks due to a stock price below $1.00. It transferred to the Nasdaq Capital Market in August 2025 and regained compliance with the minimum bid price requirement on September 11, 2025.
• Risks: Key risks include the need for additional capital, the uncertainty of clinical trial outcomes, dependence on third-party collaborators (e.g., Takeda discontinued soticlestat in Jan 2025), and potential impacts of geopolitical tensions and inflation on supply chains and costs.

Investor Verification Checklist

• Private Placement Terms: Verify the dilution impact and conversion terms of the Series B convertible preferred stock and warrants issued in the October 2025 private placement.
• OV329 Data: Review the detailed Phase 1 topline data released in October 2025 to assess the safety profile and potential for Phase 2 advancement.
• Cash Runway: Confirm the updated cash runway calculation incorporating the $75.7 million in new proceeds against current burn rates.
• Immedica Settlement: Understand the long-term implications of the $7.0 million settlement with Immedica and whether it precludes future royalty payments on ganaxolone.
• Internal Controls: Note the remediation of material weaknesses in internal controls related to fund transfers identified in 2024 following a business email compromise incident.